×
About 4,324 results

ALLMedicine™ Mastocytosis Center

Research & Reviews  1,851 results

INCREASED GROUP 2 INNATE LYMPHOID CELLS IN PERIPHERAL BLOOD OF ADULTS WITH MASTOCYTOSIS.
https://doi.org/10.1016/j.jaci.2020.09.037
The Journal of Allergy and Clinical Immunology; van der Ploeg EK, Hermans MAW et. al.

Oct 22nd, 2020 - Systemic mastocytosis is a hematological disease in which aberrant mast cells accumulate due to gain-of-function mutations in the KIT receptor. Group 2 innate lymphoid cells (ILC2s) are effector cells of type 2 immune responses that also express K...

IL-4-BATF signaling directly modulates IL-9 producing mucosal mast cell (MMC9) function...
https://doi.org/10.1016/j.jaci.2020.08.043
The Journal of Allergy and Clinical Immunology; Tomar S, Ganesan V et. al.

Oct 18th, 2020 - We have previously identified IL-9 producing mucosal mast cell (MMC9) as the primary source of IL-9 to drive intestinal mastocytosis and experimental IgE-mediated food allergy. However, the molecular mechanisms that regulate the expansion of MMC9s...

Pediatric maculopapular cutaneous mastocytosis: Retrospective review of signs, symptoms...
https://doi.org/10.1111/pde.14399
Pediatric Dermatology REFERENCES; Gurnee EA, Johansen ML et. al.

Oct 17th, 2020 - Though maculopapular cutaneous mastocytosis is the most common form of pediatric mastocytosis, it remains unclear which patients will experience severe symptoms. We sought to better define the presentation and the cutaneous and systemic signs and ...

Combined Nevus-Mastocytosis; Random Coincidence or Complex Biological Relationship?
https://doi.org/10.1097/DAD.0000000000001815
The American Journal of Dermatopathology; Van Rooyen DM, Grohs RL et. al.

Oct 15th, 2020 - Combined Nevus-Mastocytosis; Random Coincidence or Complex Biological Relationship?|2020|Van Rooyen DM,Grohs RL,Mesbah Ardakani N,|

A review of CD30 expression in cutaneous neoplasms.
https://doi.org/10.1111/cup.13894
Journal of Cutaneous Pathology; Kampa F, Mitteldorf C

Oct 13th, 2020 - The surface protein CD30 is a therapeutic target of monoclonal antibody therapy. Knowledge of the frequency of CD30 expression and its prognostic relevance is therefore interesting, not only in lymphoproliferative disorders (LPD) but also in solid...

see more →

Guidelines  3 results

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2018.0088
Journal of the National Comprehensive Cancer Network : JNCCN; Gotlib J, Gerds AT et. al.

Dec 13th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt...

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
http://www.jnccn.org/content/16/12/1500.full
Gotlib, J.

Nov 30th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt.

Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of t...
https://doi.org/10.1111/all.12436
Allergy Valent P, Escribano L et. al.

May 19th, 2014 - Mastocytosis is an emerging differential diagnosis in patients with more or less specific mediator-related symptoms. In some of these patients, typical skin lesions are found and the diagnosis of mastocytosis can be established. In other cases, ho...

see more →

Drugs  267 results see all →

Clinicaltrials.gov  2,149 results

INCREASED GROUP 2 INNATE LYMPHOID CELLS IN PERIPHERAL BLOOD OF ADULTS WITH MASTOCYTOSIS.
https://doi.org/10.1016/j.jaci.2020.09.037
The Journal of Allergy and Clinical Immunology; van der Ploeg EK, Hermans MAW et. al.

Oct 22nd, 2020 - Systemic mastocytosis is a hematological disease in which aberrant mast cells accumulate due to gain-of-function mutations in the KIT receptor. Group 2 innate lymphoid cells (ILC2s) are effector cells of type 2 immune responses that also express K...

IL-4-BATF signaling directly modulates IL-9 producing mucosal mast cell (MMC9) function...
https://doi.org/10.1016/j.jaci.2020.08.043
The Journal of Allergy and Clinical Immunology; Tomar S, Ganesan V et. al.

Oct 18th, 2020 - We have previously identified IL-9 producing mucosal mast cell (MMC9) as the primary source of IL-9 to drive intestinal mastocytosis and experimental IgE-mediated food allergy. However, the molecular mechanisms that regulate the expansion of MMC9s...

Pediatric maculopapular cutaneous mastocytosis: Retrospective review of signs, symptoms...
https://doi.org/10.1111/pde.14399
Pediatric Dermatology REFERENCES; Gurnee EA, Johansen ML et. al.

Oct 17th, 2020 - Though maculopapular cutaneous mastocytosis is the most common form of pediatric mastocytosis, it remains unclear which patients will experience severe symptoms. We sought to better define the presentation and the cutaneous and systemic signs and ...

Combined Nevus-Mastocytosis; Random Coincidence or Complex Biological Relationship?
https://doi.org/10.1097/DAD.0000000000001815
The American Journal of Dermatopathology; Van Rooyen DM, Grohs RL et. al.

Oct 15th, 2020 - Combined Nevus-Mastocytosis; Random Coincidence or Complex Biological Relationship?|2020|Van Rooyen DM,Grohs RL,Mesbah Ardakani N,|

Ranitidine - ranitidine tablet-Bryant Ranch Prepack
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10787d51-1dd5-47b4-8bd3-02f50ea26a63

Oct 15th, 2020 - Ranitidine Tablets, USP are indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more th...

see more →

News  47 results

Gene-targeting therapy shown to reduce mastocytosis symptoms
https://www.mdedge.com/familymedicine/article/219888/asthma/gene-targeting-therapy-shown-reduce-mastocytosis-symptoms?channel=39313
CHEST Physician; Richard Mark Kirkner

Mar 31st, 2020 - A small-molecule kinase inhibitor that targets a gene mutation complicit in systemic mastocytosis has been found to reduce symptoms by about 30%, according to early results of a clinical trial scheduled to be presented at the American Academy of A.

Update on Rosacea Classification and Its Controversies
https://www.mdedge.com/dermatology/article/204310/rosacea/update-rosacea-classification-and-its-controversies/page/0/1?channel=291

Jul 9th, 2019 - However, the Expert Committee still did not define either the length of time of flushing or nontransient erythema. It also did not specify convex surfaces of the face with periocular sparing as the characteristic pattern or provide additional info.

Inhibitor can improve symptoms of systemic mastocytosis
https://www.mdedge.com/hematology-oncology/article/190755/cythemias/inhibitor-can-improve-symptoms-systemic-mastocytosis?channel=50517
Jen Smith

Dec 8th, 2018 - Photo by Jen Smith Jason R. Gotlib, MD SAN DIEGO—The KIT D816V inhibitor avapritinib can improve symptoms of systemic mastocytosis (SM), according to researchers.

A Case of Systemic Mastocytosis With Associated Clonal Hematological Non-Mast Cell Lineage Disease at VA Pittsburgh Healthcare System
https://www.mdedge.com/fedprac/avaho/article/174895/lymphoma-plasma-cell-disorders/case-systemic-mastocytosis-associated
Liman AD, Gandhi A et. al.

Sep 14th, 2018 - Introduction: Systemic mastocytosis (SM) is a rare myeloid neoplasm that is caused by accumulation of abnormal mast cells in the bone marrow, liver, spleen, and skin. The KIT D816V mutation encodes a constitutively activated receptor tyrosine kina.

Avapritinib produces durable responses in SM
https://www.mdedge.com/hematology-oncology/article/184888/leukemia-myelodysplasia-transplantation/avapritinib-produces-durable
HT Staff

Jun 25th, 2018 - Photo from EHA Poster session at the 23rd Congress of the European Hematology Association (EHA) STOCKHOLM—The KIT/PDGFRA inhibitor avapritinib has produced durable responses in patients with systemic mastocytosis (SM). In the phase 1 EXPLORER tria.

see more →

Patient Education  7 results see all →